Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition
Although recent advances have added more targeted agents to the ovarian cancer armamentarium and improved outcomes for patients, the disease still carries a relatively poor prognosis with a 5-year relative survival rate of 50.9%.1 In the search to continue …